Stefan Verlohren

List of Publications by Citations

Source: https://exaly.com/author-pdf/8860048/stefan-verlohren-publications-by-citations.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83 papers

4,076 citations

31 h-index

63 g-index

101 ext. papers

4,830 ext. citations

avg, IF

5.1 L-index

| # | Paper | IF | Citations |
|----|--|---------------------|-----------|
| 83 | Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. <i>New England Journal of Medicine</i> , 2016 , 374, 13-22 | 59.2 | 761 |
| 82 | Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. <i>Circulation</i> , 2012 , 125, 911-9 | 16.7 | 411 |
| 81 | An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2010 , 202, 161.e1-161.e11 | 6.4 | 277 |
| 80 | The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 206, 58.e1-8 | 6.4 | 251 |
| 79 | Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. <i>Hypertension</i> , 2004 , 44, 271-6 | 8.5 | 226 |
| 78 | New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. <i>Hypertension</i> , 2014 , 63, 346 | .8 <u>5</u> 5-52 | 199 |
| 77 | Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015 , 45, 241-6 | 5.8 | 148 |
| 76 | Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. <i>Clinical Science</i> , 2012 , 122, 43-52 | 6.5 | 109 |
| 75 | Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. <i>Hypertension in Pregnancy</i> , 2013 , 32, 189-201 | 2 | 106 |
| 74 | Hypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequences. <i>PLoS ONE</i> , 2009 , 4, e5155 | 3.7 | 95 |
| 73 | Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. <i>Hypertension</i> , 2009 , 53, 393-8 | 8.5 | 78 |
| 72 | Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. <i>PLoS ONE</i> , 2008 , 3, e3742 | 3.7 | 74 |
| 71 | Uterine artery Doppler, birth weight and timing of onset of pre-eclampsia: providing insights into the dual etiology of late-onset pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014 , 44, 293-8 | 5.8 | 73 |
| 70 | Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. <i>Hypertension</i> , 2012 , 60, 451-8 | 8.5 | 69 |
| 69 | Uterine vascular function in a transgenic preeclampsia rat model. <i>Hypertension</i> , 2008 , 51, 547-53 | 8.5 | 69 |
| 68 | Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. <i>Obstetrics and Gynecology</i> , 2014 , 124, 265-273 | 4.9 | 63 |
| 67 | Inhibition of trophoblast-induced spiral artery remodeling reduces placental perfusion in rat pregnancy. <i>Hypertension</i> , 2010 , 56, 304-10 | 8.5 | 60 |

(2015-2018)

| 66 | Update on the Diagnosis and Prognosis of Preeclampsia with the Aid of the sFlt-1/ PlGF Ratio in Singleton Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2018 , 43, 81-89 | 2.4 | 57 |
|----|--|------|----|
| 65 | Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019 , 53, 367-375 | 5.8 | 54 |
| 64 | Effects of circulating and local uteroplacental angiotensin II in rat pregnancy. <i>Hypertension</i> , 2010 , 56, 311-8 | 8.5 | 54 |
| 63 | Endovascular trophoblast invasion, spiral artery remodelling and uteroplacental haemodynamics in a transgenic rat model of pre-eclampsia. <i>Placenta</i> , 2008 , 29, 614-23 | 3.4 | 51 |
| 62 | The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. <i>Journal of Perinatal Medicine</i> , 2014 , 42, 61-8 | 2.7 | 48 |
| 61 | Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. <i>Circulation</i> , 2012 , 126, 2990-9 | 16.7 | 48 |
| 60 | Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. <i>Fetal Diagnosis and Therapy</i> , 2015 , 37, 81-92 | 2.4 | 47 |
| 59 | Immunology in hypertension, preeclampsia, and target-organ damage. <i>Hypertension</i> , 2009 , 54, 439-43 | 8.5 | 47 |
| 58 | Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia. <i>Obstetrics and Gynecology</i> , 2016 , 128, 261-269 | 4.9 | 46 |
| 57 | Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. <i>Hypertension</i> , 2017 , 69, 1192-1197 | 8.5 | 42 |
| 56 | Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015 , 45, 286-93 | 5.8 | 41 |
| 55 | Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. <i>Circulation Research</i> , 2005 , 97, 1253-61 | 15.7 | 35 |
| 54 | Changes in endovascular trophoblast invasion and spiral artery remodelling at term in a transgenic preeclamptic rat model. <i>Placenta</i> , 2010 , 31, 320-6 | 3.4 | 33 |
| 53 | A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. <i>Hypertension in Pregnancy</i> , 2016 , 35, 295-305 | 2 | 32 |
| 52 | Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. <i>Hypertension in Pregnancy</i> , 2014 , 33, 427-39 | 2 | 28 |
| 51 | Placental expression of sFlt-1 and PlGF in early preeclampsia vs. early IUGR vs. age-matched healthy pregnancies. <i>Hypertension in Pregnancy</i> , 2017 , 36, 151-160 | 2 | 27 |
| 50 | Trophoblasts reduce the vascular smooth muscle cell proatherogenic response. <i>Hypertension</i> , 2008 , 51, 554-9 | 8.5 | 26 |
| 49 | Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. <i>Prenatal Diagnosis</i> , 2015 , 35, 386-93 | 3.2 | 25 |

| 48 | Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. <i>Hypertension in Pregnancy</i> , 2013 , 32, 459-73 | 2 | 24 |
|----|--|------|----|
| 47 | Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. <i>Hypertension</i> , 2021 , 77, 461-471 | 8.5 | 22 |
| 46 | SLC41A1 is the only magnesium responsive gene significantly overexpressed in placentas of preeclamptic women. <i>Hypertension in Pregnancy</i> , 2013 , 32, 378-89 | 2 | 20 |
| 45 | The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. <i>New England Journal of Medicine</i> , 2016 , 374, 1785-6 | 59.2 | 20 |
| 44 | Antiangiogenic factors and maternal hemodynamics during intensive hemodialysis in pregnancy. <i>Hemodialysis International</i> , 2013 , 17, 639-43 | 1.7 | 16 |
| 43 | Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia. <i>Hypertension</i> , 2020 , 75, 202-210 | 8.5 | 16 |
| 42 | From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: comprehensive approach. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020 , 55, 5-12 | 5.8 | 13 |
| 41 | Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor . <i>Pregnancy Hypertension</i> , 2017 , 8, 31-36 | 2.6 | 12 |
| 40 | Increased placental sFlt-1 but unchanged PlGF expression in late-onset preeclampsia. <i>Hypertension in Pregnancy</i> , 2017 , 36, 175-185 | 2 | 12 |
| 39 | Natural Killer Cell Reduction and Uteroplacental Vasculopathy. <i>Hypertension</i> , 2016 , 68, 964-73 | 8.5 | 12 |
| 38 | The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , | 6.4 | 12 |
| 37 | Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia. <i>American Journal of Reproductive Immunology</i> , 2018 , 80, e12988 | 3.8 | 7 |
| 36 | L13. The routine measurement of the sFlt1/PlGF ratio allows differential diagnosis of hypertensive pregnancy disorders and has prognostic potential in preeclamptic patients. <i>Pregnancy Hypertension</i> , 2011 , 1, 245-6 | 2.6 | 6 |
| 35 | Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia <i>Pregnancy Hypertension</i> , 2021 , 27, 42-50 | 2.6 | 6 |
| 34 | A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and | 4 | 6 |
| 33 | Obstetrics). International Journal of Gynecology and Obstetrics, 2021, 154 Suppl 1, 3-31 Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1762 | 3.7 | 5 |
| 32 | Kagami-Ogata syndrome: an important differential diagnosis to Beckwith-Wiedemann syndrome. <i>Journal of Clinical Ultrasound</i> , 2020 , 48, 240-243 | 1 | 5 |
| 31 | Predictive Value of the sFlt-1. Obstetrical and Gynecological Survey, 2016, 71, 273-274 | 2.4 | 4 |

| 30 | Re: Rational and irrational ratios. Ultrasound in Obstetrics and Gynecology, 2017, 49, 157-158 | 5.8 | 3 |
|----|--|----------|---|
| 29 | Pr\u00e4klampsie und hypertensive Schwangerschaftserkrankungen. Frauenheilkunde Up2date, 2009 , 3, 461 | -47.2 | 2 |
| 28 | Short Term Prediction of Preeclampsia. Maternal-Fetal Medicine, 2021, 3, 107-115 | 0.6 | 2 |
| 27 | Gestational Age-Specific Reference Ranges for the sFlt-1/PlGF Immunoassay Ratio in Twin Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2021 , 48, 288-296 | 2.4 | 2 |
| 26 | Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. <i>Pregnancy Hypertension</i> , 2021 , 25, 219-224 | 2.6 | 2 |
| 25 | Re: Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeksRgestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017 , 49, 665-666 | 5.8 | 1 |
| 24 | Role of placenta in development of pre-eclampsia: revisited. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020 , 56, 803-808 | 5.8 | 1 |
| 23 | Pr\deltaklampsie. Der Gynakologe, 2017 , 50, 213-221 | 0.1 | 1 |
| 22 | Re: uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia. P. I. Ginez-Arriaga, I. Herraiz, E. A. Lipez-Jimliez, E. Ginez-Montes, B. Denk and A. Galindo. Ultrasound Obstet Gynecol 2013; 41: 530-537. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013 , 41, 489-9 | 5.8 0 | 1 |
| 21 | FrBgeburtlichkeit. <i>Frauenheilkunde Up2date</i> , 2010 , 4, 235-247 | 0.1 | 1 |
| 20 | Prognostic significance of prenatal ultrasound in fetal arthrogryposis multiplex congenita. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 943-953 | 2.5 | 1 |
| 19 | Relevance of maternal sodium level for preeclampsia-associated adverse pregnancy outcomes. <i>Pregnancy Hypertension</i> , 2021 , 25, 110-115 | 2.6 | 1 |
| 18 | sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation <i>PLoS ONE</i> , 2022 , 17, e0263443 | 3.7 | 1 |
| 17 | Differential diagnosis of syndromic craniosynostosis: a case series. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1 | 2.5 | Ο |
| 16 | | | |
| 10 | Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction <i>Pregnancy Hypertension</i> , 2022 , 28, 149-155 | 2.6 | 0 |
| 15 | | 0.1 | 0 |
| | preeclampsia and fetal growth restriction <i>Pregnancy Hypertension</i> , 2022 , 28, 149-155 | | 0 |

| | 12 | Author ß reply re: Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018 , 125, 513-514 | 3.7 |
|---|----|---|-----|
| | 11 | Re: Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study. E. Sabri[]P. Lequerica-FernEdez, P. Lafuente-Ganuza, E. Eguia-Egeles, | 5.8 |
| | 10 | Pr\u00e4klampsierisiko \u00e4was ist zur \u00dBerwachung in der Gravidit\u00e4sinnvoll?. Der Gynakologe, 2019, 52, 845-850 | 0.1 |
| | 9 | Biomarker in der Prflataldiagnostik. <i>Der Gynakologe</i> , 2013 , 46, 397-402 | 0.1 |
| | 8 | Pr⊞klampsie. <i>Journal F⊡ Gyn</i> kologische Endokrinologie/Schweiz, 2017 , 20, 157-161 | O |
| | 7 | Re: Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia. A. Khalil, N. Maiz, R. Garcia-Mandujano, M. Elkhouli and K. H. Nicolaides. Ultrasound Obstet Gynecol 2014; 44: 402-410. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014 , 44, 386 | 5.8 |
| (| 6 | PrBklampsie und Diabetes mellitus in der Schwangerschaft. <i>Monatsschrift Fur Kinderheilkunde</i> , 2012 , 160, 1204-1210 | 0.2 |
| | 5 | Pr∄klampsie Œine Multisystemerkrankung in der Schwangerschaft. <i>Dialyse Aktuell</i> , 2008 , 12, 300-304 | 0.1 |
| , | 4 | Preeclampsia: Universal Screening or Universal Prevention for Low and Middle-Income Settings?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021 , 43, 334-338 | 1.1 |
| | 3 | Maternale Erkrankungen in der Schwangerschaft 2021 , 337-609 | |
| | 2 | Kongressnachlese. Pr\(\text{B}\)klampsie \(\text{B}\)creening/Pr\(\text{B}\)iktion/Pr\(\text{D}\)ention. \(Geburtshilfe\) Und \(Frauenheilkunde\), \(2018\), \(78\), \(1197-1200\) | 2 |
| : | 1 | The growing body of evidence for the implementation of the soluble fms-like tyrosine kinase 1/placental growth factor ratio into clinical routine. <i>American Journal of Obstetrics and Gynecology</i> , 2021 | 6.4 |